MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Safety and how the body processes the drugAnnounced or plannedPermission or regulatory step

Phase 1

PTD802: FDA clearance for the first human study

Worth knowing

The FDA allowed the first study of PTD802 to begin. PTD802 is an oral drug designed to help immature cells develop into cells that make myelin.

What this means for people with MS

This is an important step from laboratory work to human testing, but there is no evidence yet that it helps people with MS.

What kind of evidence exists?
Permission for a study in people
How reliable is this source?
Official company announcement about the permission • no results about benefit yet

Related study or programme: PTD802 →

Official research sourceRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator